FindTrial
Sign In

Hemodynamic stability during laryngoscopy and intubation with the use of Dexmedetomidine in severe mitral stenosis patients, posted for mitral valve replacement.

Use of Dexmedetomidine in attenuating the stress response to laryngoscopy and and intubation in patients undergoing mitral valve replacement for severe mitral stenosis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/12/022550
Enrollment
22
Registered
2019-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I050- Rheumatic mitral stenosis

Interventions

Intervention1: Drug Dexmedetomidine: A single dose of 0.5mcg/kg will be diluted in 100 ml volume and infused over 10 minutes using infusion pump after securing intravenous access.Following standard in

Sponsors

GB Pant Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: undergoing mitral valve replacement for severe mitral stenosis (Mitral valve area < 1cm2) with or without associated mitral regurgitation.

Exclusion criteria

Exclusion criteria: Associated other valvular lesions Coexisting hepatic, renal or severe respiratory dysfunction Coexisting coronary artery disease Ejection fraction Obesity (BMI > 30) Severe systemic disorder (uncontrolled hypertension, insulin dependent DM) Conduction abnormalities - AV block Preoperative use of alpha 2 receptor agonists Intubation attempts lasting > 20 sec

Design outcomes

Primary

MeasureTime frame
1) Haemodynamic response at 1,3,5 and 10 minutes after endotracheal intubation. Timepoint: 1) 1,3,5 and 10 minutes after endotracheal intubation.—

Secondary

MeasureTime frame
Total analgesic consumption during surgery and any other adverse effect of drugTimepoint: Throughout procedure(beginning till end)—

Countries

India

Contacts

Public ContactVarun Sharma

Delhi University

drsanjulavirmani@yahoo.co.in9718599409

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026